Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model

Leukemia

Volumn 10, Issue 1, 1996, Pages 130-137

  Mohammad, R M ^a,b   Mohamed, A N ^b   Hamdan, M Y ^a   Vo, T ^b   Chen, B ^a   Katato, K ^a   Abubakr, Y A ^a   Dugan, M C ^b   Al Katib, A ^a  

^a Department of Internal Medicine   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell; Bryostatin 1; Chronic lymphocytic leukemia; Dolastatin 10 and 15; SCID mice; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CYCLOPHOSPHAMIDE; DOLASTATIN; DOLASTATIN 10; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN LAMBDA CHAIN; LYMPHOCYTE SURFACE MARKER; MELPHALAN; METHOTREXATE; VINCRISTINE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; CASE REPORT; CELL CULTURE; CELL SUSPENSION; CHRONIC LYMPHATIC LEUKEMIA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; INTRAVENOUS DRUG ADMINISTRATION; KARYOTYPING; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 0030031864     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights in biology and therapy. Ann Intern Med 1990; 113: 525-539
2. Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis. Mayo Clin Proc 1992; 67: 349-353.
3. Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities. Mayo Clin Pro 1992; 67: 457-461.
4. Keating MJ et al. Fludarbine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
5. Kemena A et al. Phase II clinical trial of fludarabine in chronic lymphocytic leukmemia on a weekly low dose schedule. Leuk Lymphoma 1993; 10: 187-193.
6. De Rossi G et al. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. Haematologica 1993, 78: 167-171.
7. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-689.
8. Juliussin G, Elmhorn-Rosenberg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 1992; 327: 1056-1061.
9. HO AD et al. Pentostatin in refractory chronic lymphocytic leukemia. A phase II trial of the European Organization for research and treatment of cancer. J Natl Cancer Inst 1990; 82: 1416-1420.
10. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 1994; 54: 165-168.
11. Bardales RH, Al-Katib AM, Carrato A, Koziner B. Detection of intracytoplasmic immunoglobulin by flow cytometry in B cell malignancies. J Histochem Cytochem 1989, 37: 83-89.
12. Nishikori M, Hansen H, Yen A, Clarkson B. Cloning of fresh lymphoma cells. Med Pediatr Oncol 1981; 9: 167-173.
13. Pettit GR et al. Isolation and structure of bryostatin 1: J Am Chem Soc 1982; 104: 6846-6848.
14. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk Res 1993; 17: 1-8.
15. Dexler HG et al. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74: 1747-1757.
16. Maki A et al. Bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs 1995; 6: 392-397.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
18. Ravetch JV et al. Structure of the human immunoglobulin mu locus: characterizations of embryonic and rearranged J and D genes. Cell 1981; 27: 583-591.
19. Cossman et al. Molecular genetics and the diagnosis of lymphoma: Arch Path Lab Med 1988; 112: 117-127.
20. Hieter PA et al. Clustered arrangement of immunoglobulin lambda constant region genes in man. Nature 1981; 294: 536-540.
21. Al-Katib A et al. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood 1993; 81: 3034-3042.
22. Corbett TH et al. Discovery of solid tumor activity agents using a soft-agar-colony-formation disk-diffusion-assay. Cytotoxic Anti-cancer Drugs: Models and Concepts for Drug Discovery and Development. Kluwer Academic Publishers: Boston, 1992, pp 35-89.
23. Freedman AS,Nadler LM. Immunologic markers in non-Hodgkin's lymphoma Hematol Oncol Clin N, Am 1991; 5: 871-889.
24. Spier CM et al. The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. Am J Pathol 1988; 133: 118-126.
25. Magrath IT, Pizzo PA, Whang-Peng J. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. J Natl Cancer Inst 1980; 64: 465-476.
26. Magrath IT, Freeman CB, Pizzo P. Characterization of lymphoma-derived cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface marker. J Natl Cancer Inst 1980; 64: 477-483.
27. Schuchter LM et al. Successful treatment of murine melanoma with bryostatin 1. Cancer Res 1991; 51: 682-687.
28. Hornung RL, Pearson JW, Beckwith M, Longo DL. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992; 52: 101-107.